Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 346 AL 360

The leukotriene signaling pathway: a druggable target in Alzheimer's disease

Michael J, Marschallinger J, Aigner L.

Drug Discov Today. 2019 Feb;24(2):505-516. doi: 10.1016/j.drudis.2018.09.008. Epub 2018 Sep 18.

Role of Rab GTPases in Alzheimer's Disease

Zhang X, Huang TY, Yancey J, Luo H, Zhang YW.

ACS Chem Neurosci. 2019 Feb 20;10(2):828-838. doi: 10.1021/acschemneuro.8b00387. Epub 2018 Oct 11.

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies

Chen Y, Fu AKY, Ip NY.

Pharmacol Ther. 2019 Mar;195:186-198. doi: 10.1016/j.pharmthera.2018.11.006. Epub 2018 Nov 12.

Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease

Thawkar BS, Kaur G.

J Neuroimmunol. 2019 Jan 15;326:62-74. doi: 10.1016/j.jneuroim.2018.11.010. Epub 2018 Nov 20.

A vaccine against Alzheimer`s disease: anything left but faith?

Bachmann MF, Jennings GT, Vogel M.

Expert Opin Biol Ther. 2019 Jan;19(1):73-78. doi: 10.1080/14712598.2019.1554646. Epub 2018 Dec 17.

CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review

Zhao L.

Gerontology. 2019;65(4):323-331. doi: 10.1159/000492596. Epub 2018 Dec 12.

Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications

Angelucci F, Čechová K, Průša R, Hort J.

CNS Neurosci Ther. 2019 Mar;25(3):303-313. doi: 10.1111/cns.13082. Epub 2018 Nov 6.

DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease

Xu LZ, Li BQ, Jia JP.

Mol Neurobiol. 2019 Apr;56(4):2838-2844. doi: 10.1007/s12035-018-1242-2. Epub 2018 Jul 31.

Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study

Andre L, Gallini A, Montastruc F, Coley N, Montastruc JL, Vellas B, Andrieu S, Gardette V; MAPT/DSA study group.

Br J Clin Pharmacol. 2019 Jan;85(1):71-99. doi: 10.1111/bcp.13734. Epub 2018 Oct 17.

Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?

Merlo S, Spampinato SF, Sortino MA.

CNS Neurosci Ther. 2019 Jan;25(1):5-13. doi: 10.1111/cns.13050. Epub 2018 Aug 12.

Definition of Late Onset Alzheimer's Disease and Anticipation Effect of Genome-Wide Significant Risk Variants: Pilot Study of the APOE e4 Allele

De Luca V, Spalletta G, Souza RP, Graff A, Bastos-Rodrigues L, Camargos Bicalho MA.

Neuropsychobiology. 2019;77(1):8-12. doi: 10.1159/000490739. Epub 2018 Aug 15.

Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors

Takeda S.

Neurosci Res. 2019 Apr;141:36-42. doi: 10.1016/j.neures.2018.08.005. Epub 2018 Aug 16.

Scan-Time Corrections for 80-100-min Standardizetd Uptake Volume Ratios to Measure the (18)F-AV-1451 Tracer for Tau Imaging

He M, Baker SL, Shah VD, Lockhart SN, Jagust WJ.

IEEE Trans Med Imaging. 2019 Mar;38(3):697-709. doi: 10.1109/TMI.2018.2870441. Epub 2018 Sep 17.

Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials

Tsoi KK, Chan JY, Chan FC, Hirai HW, Kwok TC, Wong SY.

Clin Pharmacol Ther. 2019 Jan;105(1):121-130. doi: 10.1002/cpt.1104. Epub 2018 Jun 19.

Drug development for Alzheimer's disease: review

Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X.

J Drug Target. 2019 Feb;27(2):164-173. doi: 10.1080/1061186X.2018.1474361. Epub 2018 Jun 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias